neuroendocrine tumors

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

neuroendocrine tumors
Nov 15, 2024, 16:41 | Blog
Rahul Gosain: Current treatment landscape for NET with Pamela Kunz
Rahul Gosain, Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, shared…
Nov 13, 2024, 08:56 | Insight
Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors
Rachel Riechelmann, Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, shared…
Nov 12, 2024, 04:00 | Blog
European Society of Surgical Oncology Webinar on Pancreatic Neuroendocrine Tumors
European Society of Surgical Oncology posted on X: “3 days left until the ESSO Webinar…
Nov 10, 2024, 21:30 | Blog
Rachel Solomon: It takes 5 years on average from initial symptoms to actual diagnosis of NETs
Rachel Solomon, Associate Director, US Public Affairs and Patient Advocacy, Oncology at Sanofi, posted on…
Nov 8, 2024, 15:03 | Blog
Udhayvir Grewal: Chromogranin A is not a screening test for neuroendocrine tumors
Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport Academy Medical Centre, shared this post…
Oct 19, 2024, 09:50 | Insight
Updates on the GI and Neuroendocrine Tumors working group
Immune Oncology Research Institute shared a post on LinkedIn: "During its first year, the GI…
Oct 17, 2024, 11:32 | Blog
UF Health Cancer Center has been designated a Center of Excellence by the Pheo Para Alliance
UF Health Cancer Center shared the following on LinkedIn: “In recognition of providing the most…
Oct 16, 2024, 17:41 | Insight
Hans Hofland: Can NET become NEC (-like)?
Hans Hofland shared a post on X about a recent paper by Atsuko Kasajima et al.…
Oct 14, 2024, 13:49 | Insight
Rachel Riechelmann: Systemic review on TKI efficacy and safety in patients with neuroendocrine tumors
Rachel Riechelmann, Professor at AC Camargo Cancer Center, shared on X: “Our systemic review on…
Oct 3, 2024, 18:00 | Insight
Amol Akhade: How to manage rare endocrine and Neuroendocrine Tumors
Amol Akhade shared a post on LinkedIn: "How to manage rare endocrine and Neuroendocrine Tumors.…
Sep 21, 2024, 08:28 | Blog
Julie Hallet: Cabozantinib vs placebo for NETs
Julie Hallet, Associate Scientist at Sunnybrook Health Sciences Centre and Assistant Professor of General Surgery…
Aug 24, 2024, 11:07 | Blog
Mark Lewis: Observations from my annual dose of empathy
Mark Lewis shared a post on X: “Observations from my annual dose of empathy. 1)…
Aug 12, 2024, 22:11 | Blog
Enrique Grande: Acknowledging Grupo GETNE's contribution to neuroendocrine tumors
Enrique Grande shared on X: "Maybe we should stop one day to think and acknowledge the…
Aug 10, 2024, 03:25 | Positive
Mark Lewis: 7 years ago today these men saved my life
Mark Lewis shared on X: "7 years ago today these men saved my life. Performing…
Jul 20, 2024, 11:37 | Blog
Mark Lewis: No specialist practices successfully in a vacuum
Mark Lewis shared Michael Misialek's, Associate Chair of Pathology at Newton-Wellesley Hospital, post on X,…
Jul 7, 2024, 14:59 | Insight
Advancements in Oncology and Cancer Understanding - The Babak Lab
The Babak Lab made the following post on LinkedIn: "Weekly Digest Advancements in Oncology and Cancer…
Jul 4, 2024, 14:08 | Blog
Oncology Brothers: Starting the morning with Dr. Jason Zittel
Oncology Brothers shared a post on X: "Starting the morning with Drs. Jason Zittel, Renuka…
Jul 4, 2024, 13:40 | Insight
Comprehensive review by Dr. Renuka Iyer on NET at Upstate NY Cancer Symposium
Malak Alharbi, Hematology/Oncology fellow at Roswell Park, shared on X: "Rare cancers account for ~27%…
Jul 4, 2024, 12:20 | Blog
Aman Chauhan: Rare and aggressive cancer requires funding to develop better treatments
Aman Chauhan shared on X: "Cancer can be an especially cruel and indiscriminate illness, claiming…
Jun 15, 2024, 08:24 | Insight
Chandler Park: When to order FDG-PET scans
Chandler Park shared on LinkedIn: "Don’t order the wrong PET scan for our cancer patients:…
Jun 14, 2024, 15:47 | Blog
2024 KNOW YOUR NETs Conferance registration is open - NET Research Foundation
NET Research Foundation made the following post on X: "Our 2024 KNOW YOUR NETs Virtual…
Jun 12, 2024, 06:29 | Insight
Neuroendocrine tumors may respond better to an oncolytic virus plus immunotherapy - Sylvester Comprehensive Cancer Center
Sylvester Comprehensive Cancer Center shared on X: "Our researchers, first author, Samuel Kareff and senior…
Jun 10, 2024, 07:25 | Blog
The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 - Yale Cancer Center
Yale Cancer Center shared a post on X: “The phase III NETTER-2 trial published in The…
May 29, 2024, 12:51 | Insight
Julie Hallet: New study on NETs liver metastases from unknown primary by Patrick Starlinger and team Mayo Clinic
Julie Hallet, Pancreatic and Gastrointestinal Surgical Oncologist at IHPBA, shared a post on LinkedIn: “New study…
May 7, 2024, 16:05 | Insight
Neuroendocrine tumors - newly updated AJCC guidelines
Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center…
Apr 30, 2024, 19:30 | Blog
Nieves Martinez Lago: Critical updates in neuroendocrine tumors
Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter: “Critical…
Apr 11, 2024, 17:24 | Insight
Thor Halfdanarson: SSTR avid thyroid nodules are not rare and often seen on SSTR PET scan
Thor Halfdanarson, Vice President for the North American Neuroendocrine Tumor Society, made the following post…
Mar 13, 2024, 15:19 | Blog
Sylvester Cancer, NANETS Partner to Present Regional Conference on Multidisciplinary Management of Neuroendocrine Tumors
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and the…
Jan 26, 2024, 17:42 | Insight
Mark Lewis: The forbidden fruit of oncology
Mark Lewis shared on X/Twitter: "Cross-trial comparison is the forbidden fruit of oncology -- we…
Dec 29, 2023, 16:53 | Blog
Philip Kantoff: RayzeBio brought a new therapy to the clinic to benefit patients with neuroendocrine tumors
Philip Kantoff, Co-Founder and Chief Executive Officer at Convergent Therapeutics, shared on LinkedIn: "Congratulations to…
Sep 17, 2023, 17:10 | Blog
Mark Lewis: Quite possibly the best review of functional pancreatic neuroendocrine tumors (and their management) that I've ever read.
Quoting Mark Lewis on X/Twitter: ''Quite possibly the best review of functional pancreatic neuroendocrine tumors…
All: 31 Posts: 1 - 100
Special Coverage